Federal health advisors voted 17-1 against an experimental treatment for Lou Gehrig's disease dubbed NurOwn, although the FDA is not bound by the vote.
at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
While the FDA is not bound by the vote, it largely aligns with the agency's own strikingly negative review released earlier this week, in which staff scientists described Brainstorm's application as"scientifically incomplete" and"grossly deficient.
Brainstorm's single 200-patient study failed to show that NurOwn extended life, slowed disease or improved patient mobility. But FDA agreed to convene the panel of outside advisers after ALS patients and advocates submitted a 30,000-signature petition seeking a public meeting. FDA leaders have recently emphasized a new level of"regulatory flexibility" when reviewing experimental treatments for fatal, hard-to-treat conditions, But the agency appears unwilling to overlook the failed study results and missing information in Brainstorm's submission, including key details on manufacturing and quality control needed to establish the product's safety.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA Panel Rejects Brainstorm Cell Therapeutics ALS TreatmentBy Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
Les mer »
FDA to Review Experimental ALS Treatment This WeekThe Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig's disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease. Those advocates still face one giant hurdle: FDA...
Les mer »
| FDA advisers weigh divisive ALS drug todayThere's a heated debate over the investigational treatment called NurOwn.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »